Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501924 | 0.86 | CASP1 (0.57) | CASP1CASP3 | |
| SCHEMBL28631516 | 0.83 | KLK7 (0.53) | CASP1CASP3 | |
| SCHEMBL26226917 | 0.83 | KLK7 (0.53) | CASP1CASP3 | |
| SCHEMBL12046896 | 0.83 | CASP1 (0.56) | CASP1 | |
| Naphthalene SCHEMBL8411140 | 0.83 | CASP1 (0.57) | CASP1 | |
| SCHEMBL22117308 | 0.83 | ACE (0.57) | — | |
| SCHEMBL22117309 | 0.83 | ACE (0.57) | — | |
| SCHEMBL87319 | 0.82 | SYK (0.57) | CASP1 | |
| SCHEMBL19694834 | 0.82 | KYNU (0.56) | CASP1 | |
| SCHEMBL19694832 | 0.82 | KYNU (0.56) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138395-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-7041696-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1513844-A1 | NOVEL INTERLEUKIN-1 BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1511749-A1 | NOVEL INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040014753-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-01-22 | — | — | US | disclosed |
| US-20030236296-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003106460-A1 | NOVEL INTERLEUKIN-1 BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003104231-A1 | NOVEL INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236296-A1 | Novel interleukin-1beta converting enzyme inhibitors | IL1R1, IL1B, IL1RN | CASP1 65/4885CASP3 2072/4885 |
| US-20040014753-A1 | Novel interleukin-1beta converting enzyme inhibitors | IL1B, IL1RN, IL1R1 | CASP1 41/4885CASP3 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.